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Between January 1, 1989, and December 31, 1994, we have treated 122 
primary heart recipients with FK 506 (group I) and 121 with cyclosporine 
(group II). Fifty patients in the cyclosporine (CyA) group received no 
lympholytic induction (CyA alone) and 71 others received lympholytic 
induction with either rabbit antithymocyte globulin or OKT3 (CyA+LI). 
The mean follow-up was longer in the FK 506 group than in the CyA groups 
(3.2 -+ 1.3 vs 2.3 -+ 1.8 years;p < 0.01). Patient survival did not differ on the 
basis of the type of immunosuppression used. At 3 months after transplan- 
tation, the freedom from rejection in the FK 506 group was higher than that 
of the CyA-alone group (47% vs 22%, p < 0.01) but similar to that of the 
CyA+LI group (47% vs 53%). The linearized rejection rate (episodes/100 
patient-days) of the FK 506 group (0.09 episodes) was lower (p < 0.05) than 
that of the CyA-alone group (0.26)and the CyA+LI group (0.13). The 
requirement for pulsed steroids to treat rejection was less in common in the 
FK 506 group than in either CyA group. Eighteen patients in the CyA group 
had refractory rejections; all resolved with FK 506 rescue. Two patients in 
the FK 506 group had refractory rejection that resolved with total lymphoid 
irradiation (n = 1) and methotrexate herapy (n = 1). Patients receiving 
FK 506 had a lower risk of hypertension and required a lower dose of 
steroids. Although the mean serum creatinine concentration at 1 year was 
higher in the FK 506 group, this difference disappeared after 2 years. No 
patients required discontinuation of FK 506 because of its side effects. Our 
intermediate-term results indicate that FK 506 compares favorably with 
CyA as a primary immunosuppressant in heart transplantation. (J TIIORAC 
CARDIOVASC SURG 1996;111:764-72) 
T acrolimus (FK 506), a macrolide lactone derived from the fungus Streptomyces tsurubaensis, was 
recently approved by the Food and Drug Adminis- 
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tration for use as an immunosuppressive agent in 
liver transplantation. In vitro FK 506 has been found 
to be 10 to 100 times more potent than cyclosporine 
(CyA) in its immunosuppressive propert iesJ '  2 We 
first introduced FK 506 into clinical heart transplan- 
tation in October 1989 and have since treated 122 
primary heart recipients with this drug. This report 
summarizes our 5-year experience with the use of FK 
506 as a primary immunosuppressant i  heart trans- 
plantation. We will compare the clinical outcome of 
heart recipients treated with FK 506 with that of a 
concurrent cohort treated with a CyA-based regimen. 
Patients and methods 
Patient population. The patient population in this 
study consisted of patients who had an initial heart 
transplantation and survived for more than 7 days after 
764  
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 4 
Pham et aL 765 
transplantation. Patients who had second transplants or 
multiple organ transplants or who died within 7 days after 
transplantation because of primary graft failure were 
excluded from the analysis. 
Between January 1, 1989, and December 31, 1994, 243 
heart ransplant recipients at our center met these criteria. 
A total of 122 patients received an FK 506-based immu- 
nosuppression protocol, and 121 were treated with a 
CyA-based regimen. From January to September, 1989 all 
patients received CyA-based immunosuppression. When FK 
506 was available for clinical trial in heart ransplantation at 
our center in October 1989, all heart transplant recipients 
were considered as potential candidates for the FK 506 
protocol. CyA was used only when informed consent could 
not be obtained or when there were restrictions from third- 
party payers on the use of experimental drugs. 
The use of FK 506 was approved by the Institutional 
Review Board at the University of Pittsburgh, and in- 
formed consent was obtained from every patient. 
The demographic data for these patients are summa- 
rized in Table I. The FK 506 group had a lower mean age 
than the CyA group (34.2 _+ 22.3 vs 47.8 _+ 14.5 years;p < 
0.05). The mean duration of follow-up was longer in the 
FK 506 group (3.2 +_ 1.3 vs 2.3 _+ 1.8 years;p < 0.01). No 
significant difference was observed in the mean ischemic 
time between the CyA (206.9 _+ 63.2 minutes) and the FK 
506 groups (215.1 -+ 63.2 minutes). 
Immunosuppression protocols. In the FK 506 (Pro- 
graf ®, Fujisawa USA, Deerfield, Ill.), group (n = 122), 
patients were given methylprednisolone i  a dose of 15 
mg/kg during the operation, 5 mg/kg per day in three 
divided doses on postoperative day 1, and 0.3 mg/kg per 
day as a single dose thereafter. Methylprednisolone was 
converted to prednisone when the patient was able to 
tolerate a diet, and weaning from steroids was begun 2 
months after transplantation. I  the early phase of this 
study, FK 506 was administered 6 to 12 hours after 
transplantation, at a dose of 0.15 mg/kg per day in two 
divided doses, each over 4 hours, for a duration of 24 to 72 
hours. Because renal dysfunction was prevalent with this 
regimen, we have modified this protocol. 3 Since August 
1990, FK 506 has been given intravenously at a dose of 
0.05 mg/kg per day as a continuous infusion 6 to 12 hours 
after transplantation. As soon as the patient's gastrointes- 
tinal function returned, oral FK 506 was commenced at a 
dosage of 0.2 to 0.3 mg/kg per day in two divided doses. 
The plasma level (12-hour trough = 0.5 to 2.0 ng/ml) has 
been replaced by a whole blood FK 506 level, 4which was 
maintained at 5 to 30 ng/ml. In the first 2 months after 
transplantation, the FK 506 level was kept in the range of 
15 to 30 ng/ml. This level was gradually decreased to 5 to 
15 ng/ml according to the pattern of rejection and the 
status of the renal function. Azathioprine (2 mg/kg per 
day) was added if the serum creatinine level was higher 
than 2.0 mg/dl (to allow a reduction in the FK 506 dosage) 
or if there was persistent rejection. When a combination 
of FK 506, steroids, and azathioprine was required, endo- 
myocardial biopsies were performed monthly, and pa- 
tients have been aggressively weaned from steroids (by 5 
mg per month) to avoid major infections. 
The immunosuppression protocol for CyA plus lympho- 
lytic induction (CyA+LI; n = 71) with either OKT3 
Table I. Demographics of cardiac transplant 
recipients receiving FK 506 and CyA 
Immunosuppression 
FK 506 CyA 
No. of patients 122 121 
Age (yr) 
Mean _+ SD 34.2 + 22.3 47.8 _+ 14.5" 
Range 0-65.2 1.8-66.3 
<18 yr 42 10t 
>18 yr 80 111 
Gender 
Male 97 104 
Female 25 17 
Underlying disease 
Ischemic 37 53 
Idiopathic 31 49 
Congenital 27 3 
Other 27 16 
Ischemic time (min) 
Mean _+ SD 215.1 _+ 63.0 206.9 _+ 63.2 
Duration of follow-up (yr) 
Mean + SD 3.2 _+ 1.3 2.8 -- 1.9t 
SD, Standard deviation. 
*p < 0.05. 
tp < 0.01. 
(Orthoclone, Ortho Pharmaceutical Corp., Raritan, N.J.) 
(n = 11) or rabbit antithymocyte globulin (ATG; n = 60) 
has been described in details elsewhere. 5 ATG was pre- 
pared locally by Dr. Charles P. Bieber according to the 
method of Davis, Cooperband, and Mannick. 6 In this 
protocol, steroids were administered as previously de- 
scribed for the FK 506 group. Azathioprine (4 mg/kg) was 
administered intraoperatively and continued postopera- 
tively at a dosage of 2 mg/kg per day so long as the white 
blood cell count was greater than 3500 cells/mm 3.Cyclo- 
sporine was started within 24 hours after the operation, 
and the target rough whole blood level was maintained at 
800 to 1200 ng/ml (TDx method, Sandoz Pharmaceutical 
Corp., East Hannover, N.J.). OKT3 was administered 
intravenously at 5 rag/day for 14 days beginning on the 
second or third postoperative day, and ATG was given 
intramuscularly at 1.5 mg/kg per day during the first 5 days 
after the transplantation. 
In the group receiving CyA without lympholytic induc- 
tion (CyA alone) (n = 50), a modified triple drug regimen, 
as previously described by Bolman and associates, 7 was 
used. In brief, a preoperative loading dose of CyA (6 to 10 
mg/kg) was administered orally 2 hours before the oper- 
ation. On postoperative day 1, oral CyA was commenced 
twice a day at appropriate dosages (2 to 6 mg/kg per day) 
to maintain a trough whole blood (TDx method, Sandoz) 
level of 800 to 1200 ng/ml. Methylprednisolone at a dose 
of 15 mg/kg was given during the operation, followed by 3 
mg/kg per day in four divided doses on postoperative day 
1, and reduced to 0.4 mg/kg per day by postoperative day 
6. Methylprednisone was converted to prednisone on the 
return of the gastrointestinal function. By 1 month after 
766 Pham et al. 
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Fig. 1. Actuarial survival of cardiac transplant recipients according to different immunosuppression 
protocols. 
transplantation, the dose of prednisone was reduced to 0.3 
mg/kg, and steroids were weaned further after 6 months. 
Azathioprine was administered as in the CyA+LI group. 
Monitoring for rejection. Surveillance for rejection in- 
volves weekly endomyocardial biopsies during the first 
month, monthly for the next 3 months, and every 3 months 
for the remaining first year. Thereafter, biopsies are 
performed semiannually. In addition, endomyocardial bi-
opsies are performed whenever clinically indicated. In 
infants and small children, endomyocardial biopsies are 
performed less frequently because of the inherent echni- 
cal difficulty. Biopsy specimens are graded according to 
the criteria of the International Society for Heart and 
Lung Transplantation. 8 
Treatment of rejection. Acute rejection (grade 3A or 
higher) is treated with boluses of methylprednisolone (1 
gm/day for adults and 10 to 20 mg/kg per day for pediatric 
patients, for 3 days). Grade 1B to 2 rejections are treated 
by augmenting the baseline doses of the primary immu- 
nosuppressant (FK 506 or CyA) or steroids. OKT3 or 
ATG is reserved for steroid-resistant rejections. 
Monitoring for infection. Pretransplantation titers for 
herpesvirus, hepatitis A, B, and C viruses, and Toxoplasma 
gondii were obtained on every patient. After transplanta- 
tion, all patients were followed up by an infectious disease 
specialist. Infections were diagnosed according to previ- 
ously established criteria? Only major infections, as pre- 
viously defined, 5 that necessitated hospitalization for in- 
travenous drug therapy were included for analysis. 
Statistical analysis. Actuarial survival, freedom from 
acute rejection, and freedom from allograft coronary 
arteriopathy were computed by means of life table anal- 
ysis. These analyses were based on both the intention-to- 
treat method (data were analyzed according to the initial 
treatment assignment) and the censoring crossover 
method (crossovers were censored when treatment 
tO  11  changed). ' Survival curves were compared by means 
of the log-rank (Mantel-Cox) test. Differences in group 
means were compared by the t test, and analysis of 
variance for repeated measures with adjustment was made 
for comparisonwise error. 12 Differences in proportions 
were compared by the Z 2 test. Ap  value less than 0.05 was 
considered statistically significant. For the calculation of 
incidence rates (episodes per 100 patient-days) of rejec- 
tion, infection, requirement for steroid bolus, and lympho- 
lytic treatments of patients in the CyA group who were 
converted to FK 506, the rates were calculated from the 
time of the transplantation to the time of conversion to 
FK 506. Incidence rates were compared with the use of 
the two-sample test for incidence-density measure. 13 A 
software package (CSS Statistica, Release 4.5, Statsoft, 
Tulsa, Okla.) was used for statistical analyses. 
Results 
Patient survivals. According to the intention-to- 
treat analysis, the 1- and 5-year actuarial patient 
survivals did not differ significantly on the basis of 
the type of immunosuppressive protocols (CyA 
alone, 91% and 74%; CyA+LI ,  93% and 69%; FK 
506, 90% and 76%) (Fig. 1). Because the intention- 
to-treat analyses have been criticized for not evalu- 
ating the true effect of the treatment in studies in 
which there are significant crossovers (15% of pa- 
tients receiving CyA initially were converted to FK 
506 [see below]), we have analyzed the survival data 
using both the intention-to-treat nd the censoring 
crossover methods, l°' 11 In the former method, data 
are analyzed according to the initial treatment as- 
signment; in the latter, data are censored when 
there is a change in treatment (crossover). There 
was no difference in patient survivals according to 
the types of immunosuppressive protocols when 
either method was used. 
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Causes of death. Twenty-four patients in the FK 
506 and 23 in the CyA groups (CyA alone and 
CyA+LI) died during this study (p = not significant; 
Table II). The most common causes of death for 
both groups were rejection and infection. Three 
patients died of disseminated posttransplant lym- 
phoproliferative disease, one in the FK 506 group 
and two in the CyA group. Four patients in the CyA 
group died of other malignancies including lung 
tumor (n = 1), testicular tumor (n = 1), osteosar- 
coma (n = 1), and recurrent cardiac rhabdomyosar- 
coma (n = 1). 
Acute rejection. The actuarial freedom from re- 
jection at 3 months for the CyA-alone group was 
22%, significantly lower (p < 0.01) than that of the 
CyA+LI (53%) and FK 506 groups (47%) (Fig. 2). 
The incidence rate of rejection (episodes per 100 
patient-days) in the FK 506 group was significantly 
lower (p < 0.05) than that of the CyA-alone or 
CyA+LI group (Table Ill). Steroid boluses used to 
treat rejection were lower in the FK 506 group than 
in the CyA-alone (p < 0.01) and the CyA+LI (p < 
0.05) groups. There were fewer rejection episodes 
that necessitated lympholytic treatment in the FK 
506 group than in the CyA-alone group (p < 0.01). 
Intractable rejection. Thirteen patients in the 
CyA-alone group and five in the CyA+LI group 
(four with ATG and one with OKT3) had refractory 
rejection that was resistant to conventional therapy 
with at least one course of pulse d steroids and one 
course of lympholytic treatment. All 18 of these 
patients were successfully treated by conversion to 
FK 506. Only two pediatric patients in the FK 506 
group had refractory rejection. One required total 
lymphoid irradiation and the other was treated 
successfully with methotrexate. 
Allograft coronary arteriopathy. Allograft coro- 
nary arteriopathy after transplantation was defined 
as any luminal irregularity and any coronary stenosis 
seen on the Coronary angiogram or any diffuse 
coronary artery disease at autopsy. In 183 Patients 
whose allograft coronary arteries could be evalu- 
ated, the actuarial freedom from allograft coronary 
arteriopathy at4 years for the FK 506 (103 patients) 
and CyA (80 patients) groups was 82% and 73%, 
respectively (p = not significant) (Fig. 3). 
Requirement for steroids and azathioprine. At 
most recent follow-up examination or at the time of 
death, 40 of 83 adults receiving FK 506 (48%) were 
free of steroids as compared with 16 of 95 adults 
receiving CyA (17%) (p < 0.01). Among those who 
were still receiving steroids, the average daily dose 
Table II. Causes of death during FK 506 and CyA 
immunosuppression 
lmmunosuppression 
FK 506 CyA 
No. of patients 122 121 
No. of deaths 24 (20%) 23 (19%)* 
Causes of death 
Acute rejection 2 (2%) 4 (3%) 
Allograft CAD 3 (2%) 5 (4%) 
Infection 6 (5%) 3 (2%) 
Malignancy 
PTLD 1 (0.8%) 2 (2%) 
Others 0 (0%) 4 (3%) 
Miscellaneous 12 (10%) 7 (6%) 
CAD, Coronary artery disease; PTLD, 
disease. 
*p = Not significant. 
posttransplant lymphoproliferative 
of prednisone was 5.8 _+ 2.6 mg in the FK 506 group 
and 8.0 _+ 4.5 mg in the CyA group (p < 0.01). The 
most significant impact of FK 506 has been in the 
pediatric patients; 76% of the 42 pediatric recipients 
treated with FK 506 were free of steroids. Of the 10 
pediatric patients (age = 1.8 to 17 years) who were 
initially given CyA, eight required conversion to FK 
506 because they could not be weaned from steroids; 
all of these were eventually free of steroids. 
Azathioprine was added to the steroid/FK 506 
regimen when serum creatinine concentration was 
higher than 2 mg/dl or when there were at least two 
consecutive pisodes of acute rejection that neces- 
sitated treatments. At latest follow-up, 43% Of pa- 
tients receiving FK 506 were also receiving azathio- 
prine. 
Infection. A total of 70 episodes (0.05 episodes 
per 100 patient-days) ofmajor infections occurred in 
the FK 506 group as compared with 59 episodes 
(0.06 episodes per 100 patient-days) in the CyA groups 
(p = not significant). The prevalence of bacterial; viral, 
and fungal infection was not significantly different 
between the FK 506 and CyA groups. 
Nephrotoxieity. The effect of FK 506 on renal 
function was most pronounced uring the first year 
after transplantation i both adult and pediatric 
patients, inasmuch as the mean serum creatinine 
concentration was much higher (p < 0.01) after the 
first year (adult = 2.1 _+ 0.5 mg/dl; pediatric = 0.9 _+ 
0.5 mg/dl) when compared with the pretransplanta- 
tion values (adult = 1.1 _+ 0.5 mg/dl; pediatric = 
0.6 _+ 0.3 mg/dl). The rise in serum creatinine 
concentration leveled off after the first postopera- 
tive year. In the adult patients (age >18 years) mean 
768 Pham et al. 
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Fig. 2. Freedom from acute rejection (grade 3A or higher) according to different immunosuppression 
protocols. The actuarial freedom from rejection in patients who received triple-drug therapy without 
lympholytic induction (CyA alone) was lower (p < 0.01) than that of the FK 506 group. No difference in 
the freedom from rejection between the FK 506-treated patients and the CyA-treated patients who 
received lympholytic induction. 
Table Ill. Rejection, and requirement for steroid 
boluses and lympholytic treatments under different 
protocols 
Immunosuppression 
FK 506 CyA QvA + LI 
Rejection-flee rate at 30 days 47% 22%? 53% 
Episodes of rejection (No.)* 0.09 0.26? 0.135; 
Steroid bolus (No.)* 0.09 0.20:) 0.11:~ 
Lympholytic treatment (No.)* 0.009 0.06? 0.02 
*Number per 100 patient-days. 
tP < 0.01 compared with FK 506 group. 
~cp < 0,05 compared with FK 506 group. 
serum creatinine levels at 1 and 2 years after trans- 
plantation were higher in the FK 506 group than in 
the CyA groups (Fig. 4). However, this difference 
did not reach statistical significance (by the analysis 
of variance for repeated measures). 
Renal failure necessitating dialysis or kidney 
transplantation developed in five patients in the FK 
506 group and in seven in the CyA groups 2 to 5 
years after transplantation. I  the CyA groups, three 
patients required dialysis while being treated with 
CyA alone and four required dialysis after being 
converted to FK 506. Of these four patients 
switched to FK 506, two had infections (one mucor- 
mycosis and one tuberculosis) that necessitated an- 
tibiotics with nephrotoxicity. 
Other  s ide  e f fec ts  
Hypertension. The prevalence of new-onset hy- 
pertension in adults in the FK 506 and CyA groups 
was 47% (39/83) and 84% (80/95), respectively (p < 
0.01). In the pediatric group, 10% of the patients 
treated with FK 506 had hypertension. 
Hyperkalemia. Twenty-five adults and one pediat- 
ric patient (21%) who were receiving FK 506 had 
persistent hyperkalemia (K ÷ >5.0 mEq/L) that ne- 
cessitated treatment. This was easily controlled with 
a low dose of fludrocortisone (0.2 mg/day). No 
patient died of hyperkalemia n this trial. 
Diabetes mellitus. The prevalence of new-onset 
insulin-dependent diabetes mellitus was the same in 
adults in both the FK 506 (26%) and CyA (22%) 
groups. New-onset insulin-dependent diabetes mel- 
litus developed in one of 50 pediatric patients 
receiving FK 506 (both as a primary agent and after 
conversion from CyA). 
Posttransplant lymphoproliferative disease and 
other malignant diseases. Posttransplant lymphopro- 
liferative disease developed in two pediatric patients 
in the FK 506 group at 4 and 5 mouths after 
transplantation. I  one patient he disease resolved 
with reduction in immunosuppression; the other 
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Fig. 3. Actuarial freedom from allograft coronary artery disease (CAD) in patients who received FK 506 
versus those who received CyA-based regimen (with and without lympholytic nduction). No difference was 
observed between the two groups (p = 0.07). 
patient died of disseminated posttransplantation 
lymphoproliferative disease. Another pediatric pa- 
tient, who initially received CyA, died of dissemi- 
nated posttransplantation lymphoproliferative dis- 
ease after conversion to FK 506. Of the adult 
patients, one in the CyA group died of brain lym- 
phoma; four in the CyA group died of other malig- 
nancies, including osteosarcoma (n = 1), recurrent 
cardiac rhabdomyosarcoma (n = 1), lung carcinoma 
(n = 1), and testicular embryonal cell carcinoma 
(n = 1). 
Other side effects of FK 506, which have been 
reported elsewhere 16and included extremity pares- 
thesis, akinetic mutism, myalgia, and tremor, were 
infrequent and transient. Notably absent in the 
FK 506 group were gingival hyperplasia, hirsut- 
ism, and coarsening of facial features. No patients 
in the FK 506 group had severe and persistent 
adverse events that required discontinuation of 
this drug. 
Discussion 
Although chemically unrelated, FK 506 and CyA 
both inhibit the immune response via their ability to 
prevent he transcription of lymphokine genes after 
the activation of T-cell receptors. 14 Both act early in 
the cell cycle and thus are very effective as immu- 
nosuppressants. Since its discovery by Ochia and 
associates 15in 1987, FK 506 has been extensively 
studied. In vitro, FK 506 suppressed the prolifera- 
tive response in mixed lymphocyte cultures by in- 
hibiting interleukin-2 synthesis after alloactiva- 
tion.1, 2, 16 In vivo, FK 506 effectively prevented and 
reversed rejection to various allografts in different 
animal models. 16-18 FK 506 was initially introduced 
into clinical use in 1989 by Starzl and colleagues 19
for the treatment of liver, kidney, and pancreas 
recipients. After the initial success of FK 506 as a 
primary and rescue agent in clinical organ transplan- 
tation, 2°-22 randomized mu!ticenter t ials both in the 
United States and in Europe with liver transplant 
recipients have indicated that FK 506 is effective and 
superior to CyA as an immunosuppressive 
agent. 23-25 FK 506 was finally approved by the Food 
and Drug Administration for use in clinical liver 
transplantation in 1994. We first introduced FK 506 
into clinical heart transplantation in October 1989. 
Our initial experience with this drug as a primary 
and rescue agent indicated that FK 506 was an 
effective immunosuppressant d was well tolerat- 
ed. 3 The intermediate-term data reported herein 
confirm our initial findings. Although the survival is 
the same in both groups, an FK 506-based regimen 
results in a lower rate of acute and refractory 
rejection than does a CyA regimen. The effect of FK 
506 was most pronounced when it was compared 
with a CyA-based regimen that included no lympho- 
lytic induction. In addition, FK 506 was associated 
with a lower risk for hypertension and fewer require- 
ment for steroids. 
The fact that 15% of the patients in the CyA 
groups were successfully converted to FK 506 for 
refractory rejection reflects, in part, the more potent 
immunosuppressive properties of FK 506 and, in 
770 Pham et al. 
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Fig. 4. Serum creatinine levels at various time points after transplantation in adult cardiac recipients 
receiving FK 506 and CyA. One year after transplantation, the serum creatinine l vels were significantly 
higher than the pretransplant (PreTx) values for both groups (p < 0.01). There were no statistically 
significant difference in the serum creatinine concentrations between FK 506 and CyA groups. 
part, our philosophy to minimize the use of multiple 
courses of high-dose steroids and lympholytic ther- 
apy. In our earlier experience with FK 506 as a 
"rescue" drug for refractory rejection, we observed 
a very high incidence of posttransplantation lympho- 
proliferative disease, especially in patients who had 
received multiple courses of steroids and lympho- 
lytic agents before being converted to FK 506. 26 
Excessive use of lympholytic treatments is a primary 
risk factor in the development of posttransplanta- 
tion lymphoproliferative diseases We therefore 
strongly believe that early conversion to FK 506 in 
patients with refractory rejection who are being 
treated with CyA should reduce this risk. 
Renal toxicity is a major side effect of both FK 506 
and CyA. Studies in liver recipients have shown that 
nephrotoxicity was comparable between CyA and 
FK 506 and that the mean serum creatinine l vels at 
various time points after transplantation were simi- 
lar in the two groups. 23' 25 In the current study, 1 
year after transplantation, patients in the FK 506 
group had slightly higher mean serum creatinine 
levels than those in the CyA group (p = not 
significant). However, this difference disappeared 
after 2 years. The higher serum creatinine level at 1 
year after transplantation i the FK 506 group 
probably reflects our learning curve in the use of this 
drug. With experience, we believe that this differ- 
ence will disappear. Hyperkalemia is a known side 
effect of FK 506 and has been reported to be 
independent of renal function. 2s' 29 This side effect 
was, however, easily treated with a small dose of 
fludrocortisone. Possible mechanisms responsible 
for the hyperkalemia include the inability of the 
distal renal tubules to respond to aldosterone (type 
IV renal tubular acidosis) and a decrease in the level 
of plasma renin caused by a depressed cellular 
activity of the juxtaglomerular system. 3°" 31 
The risks of infection and posttransplantation 
lymphoproliferative diseases were similar with both 
FK 506 and CyA. Other advantages of FK 506 over 
CyA include a lower risk of the development of 
new-onset hypertension, the lack of gingival hyper- 
plasia, and the lack of coarsening of facial features. 
Although the current study is limited by a lack of 
randomization and involves a different organ, it 
yields results similar to those of the randomized 
studies with liver and lung transplantation. I  the 
European multicenter t ial, which consisted of 545 
primary liver recipients, the rate of patient and graft 
survival was similar between FK 506 and CyA 
grouPs; however, patients receiving FK 506 had 
significantly fewer episodes of acute, refractory 
25 acute, and chronic rejection. The multicenter t ial 
in the United States consisting of 529 primary liver 
recipients reported similar results. 23 The 1-year 
actuarial survivals were similar between FK 506 and 
CyA arms, and patients receiving FK 506 had fewer 
episodes of acute, steroid-resistant, and refractory 
rejection. Our own randomized trial of FK 506 in 
lung transplantation, 32 which involved 74 lung recip- 
ients (38 received FK 506 and 36 CyA), reported the 
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same findings. The 1-year survival was similar be- 
tween the two groups; however, patients in the FK 
506 arm had significantly fewer episodes of acute 
and refractory rejection. 
In summary, FK 506 has proved to be an effective 
immunosuppressive agent in clinical cardiac trans- 
plantation. The intermediate-term esults indicate 
that the patient survival is similar with FK 506 and 
CyA immunosuppression. However, patients receiv- 
ing FK 506 have fewer episodes of acute and 
refractory rejection, require less treatment for rejec- 
tion, and need lower doses of maintenance steroids. 
Major side effects of FK 506 and CyA are similar. 
FK 506, therefore, is a useful drug in clinical heart 
transplantation. 
We thank Howard R. Doyle, MD, and Alfred Cecchetti, 
MSc, for their advice on statistical methods. 
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Discussion 
Dr. Eric A. Rose (New York, N.Y.). It is clear that FK 
506 is a valuable addition to our armamentarium of
immunosuppressive agents. It is at least equal to CyA as a 
maintenance immunosuppressive agent with regard to 
survival, and it is superior with regard to morbidities 
including gingival hyperplasia, hirsutism, and hyperten- 
sion. 
I am concerned, however, about the claim that FK 506 
offers advantages over CyA-based immunosuppression 
with regard to the frequency and severity of acute rejec- 
tion episodes. It must be pointed out, as Dr. Pham has 
mentioned, that this was not a blinded randomized trial 
and that enthusiasm for a new agent may often engender 
subtle therapeutic biases that may compensate he validity 
of seemingly significant findings. The manuscript de- 
scribes the strategy of boosting FK 506 doses in the 
presence of histologically mild rejection episodes in the 
FK 506 group. In contrast, no comparable strategy of 
increasing CyA doses in the control group is described. 
This discrepancy raises the question that the lower fre- 
quency of refractory rejection and the higher quantities of 
steroids used in the CyA-treated group were due to this 
difference in dosing strategy rather than intrinsic differ- 
ences between the two drugs. 
This report also shows that with regard to nephrotox- 
icity and development of late graft atherosclerosis, FK 506 
offers no advantage over CyA. It remains clear that these 
two problems, particularly the latter, remain the Achilles 
heel of presently available immunosuppressive regimens. 
Perhaps the most impressive finding in this experience 
is the successful treatment of rejection refractory to 
conventional treatment in 18 CyA-treated patients by 
switching to FK 506. The clinical importance of this 
observation cannot be overestimated and provides trans- 
plant groups with a powerful new tool for an otherwise 
unmanageable problem. 
I have the following questions: 
Is a randomized maintenance immunosuppression trial 
between these two agents planned for heart transplant 
recipients? If not, is FK 506 the authors' immunosuppres- 
sive agent of choice for maintenance immunosuppression? 
Can FK 506 and CyA be used in combination? 
Could FK 506 be used to initially treat acute rejection 
episodes in CyA-treated patients instead of steroids or 
anti-T-cell antibodies? 
Last, is the cost of this newly approved rug comparable 
with the cost of CyA? 
Dr. Aldo R. Castaneda (Genolier, Switzerland). Is this 
drug available for everybody, or is it still a controlled 
substance, so to speak? 
Dr. Pham. To answer Dr. Castaneda's question, this 
drug has been approved by the Food and Drug Adminis- 
tration for use in liver transplantation. However, we, as 
cardiac surgeons, can use this drug as an off-labeled rug. 
So it is available for everybody to try. 
Dr. Rose, with regard to the randomized trial, a multi- 
center trial is going to be conducted in the United States. 
In Europe, single-center trials comparing CyA and FK 506 
in heart transplantation have been initiated. 
The second question was whether FK 506 was our 
immunosuppression f choice. The answer is yes. We 
prefer this medication over CyA for all of the advantages 
that I have alluded to. Mainly, it is easier to manage the 
FK 506-treated patients because there is less rejection 
and fewer side effects. Compared with CyA, FK 506 has 
fewer cosmetic side effects, such as cushingoid features, 
hirsutism, and gingival hyperplasia. As you know, after the 
patients recover from an acute disease, cosmetic issues 
become a real concern for them. FK 506, therefore, 
certainly has these additional ~idvantages over CyA. 
The third question was whether FK 506 could be used 
in combination with CyA. In vitro, FK 506 and CyA are 
synergistic in their immunosuppressive properties. How- 
ever, as far as I know, nobody has tried to combine these 
medications in a clinical setting, I suppose, because of the 
fear of renal toxicity and the complexity of monitoring 
these two drug levels at the same time. 
The last question was whether FK 506 could be used 
initially to treat the rejection in the CyA-treated patient 
instead of steroids or anti-T-cell antibodies. The answer is 
yes. As we have learned over the past 5 years, there was a 
higher incidence of posttransplantation lymphoprolifera- 
rive disease in patients who require FK 506 rescue for 
rejection that was refractory to other immunosuppressive 
agents. Because of this problem, we are now more aggres- 
sive in converting our patients to FK 506. We have 
aggressively switched our CyA-treated patients to FK 506 
when they have rejection, and we try intentionally not to 
treat them with multiple doses of steroids and antilym- 
pholytic agents. 
Regarding the cost of this drug, I was told that this 
agent was as comparable in terms of cost to CyA, but I do 
not know the details. 
My final comments are to clarify one point Dr. Rose 
made in regard to the strategy of boosting FK 506 doses 
in the presence of histologically mild rejection episodes. 
We did the same with the CyA-treated patient if the 
CyA level was not considered to be optimal. Therefore, 
the dosing strategy is similar between the two groups of 
patients. 
